Search
News

2014 Highlights

10th December 2014 | General

What a year 2014 has been! We've put together a brief round up of the highlights from Cobra...

Back in January we launched a fresh new website, with a rejuvenated design and user-friendly content, which allows visitors quick access to a host of information. Take a virtual tour of our facilities!

February saw a boost to our GMP certification following an inspection by the MPA at our mammalian production facility in Södertälje. What the enhanced certification means for our customers.

In March we announced our partnership with BioCancell, a targeted cancer therapy company, to manufacture promising cancer drug BC-821; Phase I trials to commence in 2015.

A sunny start to spring saw the French MESR recognise Cobra as approved service provider for antibody and recombinant protein services for the research tax credit Le Crédit d’Impôt Recherche.

Prokarium, a biotech company based within our Keele facility, was spun out from Cobra in order to focus solely on vaccine development, advancing their Vaxonella® platform and product pipeline.

In May we welcomed Dr Daniel C Smith as Chief Scientific Officer at Cobra, with the responsibility for developing the highest level of scientific excellence across the group. Find out more about Dan.

At BIO this summer we announced the exciting news of our strategic collaboration with QuiaPEG Pharmaceuticals, focused on the processing of biological drugs using a novel PEGylation platform.

We’ve also been working alongside Oxthera and SymbioPharm to develop an innovative bacterial pharmaceutical product for the treatment of Primary Hyperoxaluria as part of the ELIMOX project.

Not forgetting the numerous articles and publications the team have been working on! Links and free downloads available here.

***

In line with our growth strategy, we have further invested in our manufacturing facilities. As you may already know, the company expansion began in 2011 with the acquisition of a purpose built aseptic manufacturing facility, and then in late 2013 we further expanded our antibody GMP production capacity in response to strong customer demand, this year successfully completing our first 1000L batches.

***

2015 also promises to be an exciting year for Cobra with further growth plans, upcoming collaborations, and various internal developments with the aim to improve our service offering for customers present and future. Keep an eye out for more news coming soon!
comments powered by Disqus
In order to provide complete functionality, this web site needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site. It is recommended that you allow all cookies. Allow all cookies